The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility declining almost 8%, on average, this week after a 22% jump the previous week and a 6.5% decline the week before that. Last week’s increase was based on a number of favorable Q3 financial reports but this week’s decline is based on no news of note. Here’s how they rank, in ascending order, according to their performances this week, last week and YTD.
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Read: GH Research Reports Third Quarter Financial Results and Provides Business Updates
SummaryThe munKNEE Psychedelic Drug Stocks Index was down 7.7% this week, up 22.0% the previous week and down 6.5% the week before that, and is now down 24.4% YTD.More By This Author:
